Stay updated with breaking news from Diagnostic Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Poster presentation by Pr. Christophe Le Tourneau featuring first OS and PFS data from phase I expansion study of NBTXR3 as a single agent activated by radiotherapy in tough-to-treat HNSCC population
(1) New data with additional patients and further follow up from Study 1100, evaluating lead product candidate NBTXR3 in combination with anti-PD-1 in head and neck cancer, lung metastasis and/or liver metastasis New data with additional patients and further follow up on safety and response rate from Study 102 dose expansion, evaluating NBTXR3 as a single agent activated by radiotherapy in head and neck cancer Long term safety data from complete European phase II/III registration study, Act.In.Sarc, evaluating NBTXR3 as a single agent activated by radiotherapy in soft tissue sarcoma "From ben...
Today, Amazon Web Services (AWS) launched the next phase of Diagnostic Development Initiative and expanded funding scope.